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Abstract
Objective—Data from the 2003 and 2007 National Survey of Children’s Health (NSCH) reflect 
the increasing prevalence of parent-reported ADHD diagnosis and treatment by health care 
providers. This report updates these prevalence estimates for 2011 and describes temporal trends.
Corresponding author: Susanna Visser, M.S., National Center on Birth Defects and Developmental Disabilities, Centers for Disease 
Control and Prevention, E-88, 1600 Clifton Road, Atlanta, GA 30340; 404-498-3008, fax: 404-498-3060, svisser@cdc.gov. 
None of the authors have any conflicts of interests to declare.
Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention.
HHS Public Access
Author manuscript
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2015 June 19.
Published in final edited form as:













Method—Weighted analyses were conducted with 2011 NSCH data to estimate prevalence of a 
parent-reported ADHD diagnosis, current ADHD, current medication treatment, ADHD severity, 
and mean age of diagnosis for US children aged 4–17 years and among demographic subgroups. A 
history of ADHD diagnosis (2003—2011) as well as current ADHD and medication treatment 
prevalence (2007–2011) were compared using prevalence ratios and 95% confidence intervals.
Results—In 2011, 11% of children aged 4–17 years had ever received an ADHD diagnosis (6.4 
million children). Among those with a history of ADHD diagnosis, 83% were reported as 
currently having ADHD (8.8%); 69% of children with current ADHD were taking medication for 
ADHD (6.1%, 3.5 million children). A parent-reported history of ADHD increased by 42% from 
2003—2011. Prevalence of a history of ADHD, current ADHD, medicated ADHD and moderate/
severe ADHD increased significantly from 2007 estimates. Prevalence of medicated ADHD 
increased by 28% from 2007—2011.
Conclusions—An estimated two million more US children aged 4–17 years had been diagnosed 
with ADHD in 2011, compared to 2003. More than two-thirds of those with current ADHD were 
taking medication for treatment in 2011. This suggests an increasing burden of ADHD in the US. 
Efforts to further understand ADHD diagnostic and treatment patterns are warranted.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder with 
childhood onset.1 Children with ADHD experience clinically significant functional 
impairment across settings (for example at home, in school, and with friends), resulting in 
higher rates of unintentional injury, emergency room visits, peer problems, and academic 
failure.2–7 Approximately one-third of children diagnosed with ADHD retain the diagnosis 
into adulthood, supporting the recognition of ADHD as a chronic health condition.8
Best practices for diagnosing and treating ADHD exist and include conducting a clinical 
diagnostic evaluation, incorporating information from multiple respondents (e.g., parents, 
child, teachers, child care staff) and across multiple settings (e.g., home, school, child care), 
and evaluating the child for co-occurring conditions.9,10 ADHD medication has long been 
used to effectively treat ADHD symptoms of impulsivity, inattention, and hyperactivity and 
is the single-most effective treatment for reducing ADHD symptoms.11,12 High-quality 
behavioral interventions can also improve functional outcomes of select children with 
ADHD, but may not be as broadly available across the US.13,14
Characterizing the evolving epidemiology of ADHD informs the public health impact of 
diagnosis and treatment within communities, allows for tracking changes over time, informs 
service use and needs, and provides a context for interpreting the impact of health alerts 
extending from adverse event reporting systems.15–18 Population-based epidemiological 
estimates of ADHD can come from a variety of sources. Analyses of insurance claims data 
have documented steady increases in prevalence of ADHD diagnoses between 2001 and 
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2010,19,20 however studies based on claims data are not necessarily representative of the 
uninsured or under-insured. A recent, large-scale community-based study from four school 
districts across two states suggests that the prevalence among elementary-aged children is 9–
11%21; however community-based studies are resource-intensive and are often not 
generalizable to other communities. Large-scale surveys of parents that ask about clinician-
diagnosed conditions provide an important cross-sectional picture of the impact of disorders, 
including ADHD, and can be repeated over time for surveillance purposes. Parent surveys 
can also be used to estimate both national and state-based prevalence of conditions.
Since 1996, parent reports of health care provider-diagnosed ADHD in childhood have been 
collected by nationally-representative health surveys, beginning with the National Health 
Interview Survey (NHIS).22 The reports of a diagnosis by a health care provider is a proxy 
for underlying ADHD, asking parents “Has a doctor or other health care provider ever told 
you that your child had attention deficit disorder (ADD) or attention-deficit/hyperactivity 
disorder (ADHD)?” This report of an ADHD diagnosis was included in the 2003, 2007, and 
2011 National Survey of Children’s Health (NSCH), which is a periodic parent survey of the 
physical and emotional health of US children, 0–17 years of age.23,24 Increases in parent-
reported ADHD diagnosis and medication treatment have been documented using data from 
NHIS and NSCH; average annual increases in parent-reported ADHD diagnosis ranged from 
3%–6% per year since the late 1990s.25–27
Based on data from the 2007 NSCH, an estimated 9.5% of children 4–17 years of age had 
been diagnosed with ADHD; 78% of those children were characterized by their parents as 
having current ADHD, representing 7.2% (4.1 million) of school-aged children.27 The 
estimated prevalence increased by 22% from 2003–2007 with an average annual increase of 
5.5% per year from 2003–2007. Increases in prevalence were greatest among groups with 
historically lower rates of ADHD: older teens, Hispanics, and children who spoke a primary 
language other than English. Two-thirds of those with current ADHD were taking 
medication in 2007. ADHD medication treatment increased with ADHD severity. Nearly 1 
in 20 (4.8%) of US children 4–17 years of age (2.7 million children) were taking ADHD 
medication in 2007, which is consistent with a 2008 Medical Expenditure Panel Survey 
estimate of 5.1% among children 6–12 years of age.28
Data from the most recent NSCH allow for updated estimates of parent-reported ADHD 
diagnosis and treatment, and inspection of trends in these estimates over time. Based on 
previous reports, average annual growth rates of 3–6% for parent-reported ADHD diagnosis 
and a commensurate increase in parent-reported ADHD medication treatment were 
expected.
Method
The NSCH is a national cross-sectional, random-digit-dialed telephone survey conducted in 
2003–2004 (“2003”), 2007–2008 (“2007”), and 2011–2012 (“2011”).23,24,29 The NSCH 
uses the sampling frame of the National Immunization Survey30; because of the rise in the 
prevalence of cell-phone-only households, the 2011 NSCH added a sample of cell-phone 
numbers. Between February 2011 and June 2012, 95,677 interviews were completed, 
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resulting in landline and cell-phone interview completion rates of 54.1% and 41.2%, 
respectively, and a 23.0% overall response rate.29 Sample weights were utilized to adjust for 
unequal probability of selection of households and children, nonresponse, and the 
underlying demographic distribution of US non-institutionalized children. The survey 
questions pertaining to ADHD diagnosis and treatment are included as a supplement to this 
article. A responding parent or guardian (referred to hereafter as “parent”) was asked 
questions about one randomly selected child (aged 0–17 years) in the household. Analyses 
were conducted in SAS-callable SUDAAN version 11.0 (RTI International; Cary, NC) to 
account for the complex survey design and application of sample weights.
At all three time points, parents were asked if “a doctor or other health care provider ever 
told you that [child] had Attention Deficit Disorder or Attention-Deficit/Hyperactivity 
Disorder, that is, ADD or ADHD?” In 2007 and 2011, parents who reported a history of 
ADHD were asked whether the child currently had ADHD, and in 2011, they were asked the 
age at which the child was diagnosed. Parents reporting current ADHD also described the 
severity of ADHD (mild, moderate or severe). In each survey year, a question was included 
asking about current medication treatment for ADHD, however a different subset of parents 
were asked this question in 2003 as compared to subsequent surveys. In 2003, parents who 
reported that their child had ever received a diagnosis were asked about current medication 
treatment, while in 2007 and 2011, only parents reporting current ADHD were asked about 
current medication treatment; this prohibited direct comparisons of medication for ADHD 
across the three surveys. Data allowed for direct comparisons of ever-diagnosed ADHD 
(2003—2011), current ADHD (2007—2011), ADHD severity (2007–2011), and current 
medication for ADHD (2007—2011). Independent of ADHD diagnosis, all parents were 
asked if their child had received treatment or counseling from a mental health professional 
in the past 12 months.
Data Analysis
For the 2011 survey data, estimated prevalence of a history of parent-reported ADHD 
diagnosis (ever-diagnosed), current ADHD, and current medication treatment were 
calculated for children aged 4–17 years, and compared across demographic subgroups using 
prevalence ratios (PRs). Mean age of diagnosis was calculated overall and contrasted with 
severity using a Wald F-test.
The demographic groups and subgroups were comparable to those used in the previous 
reports describing the 2003 and 2007 data27,31 to allow direct comparison of the estimates 
over time. Estimated prevalence of ever-diagnosed ADHD in 2011 was compared to 2003 
and 2007 NSCH estimates using PRs; differences in rate of change over time was tested 
with a Wald F-test comparing the combination of yearly indicator regression coefficients. 
Estimates of current ADHD and current medication treatment from 2011 were compared to 
2007 using PRs and 95% confidence intervals (CI). Demographic subgroup differences for 
change over time were tested by a Wald F-test on an interaction term. Parent-report of 
treatment or counseling by a mental health professional was combined with medication 
treatment to estimate ADHD treatment prevalence among children with current ADHD; the 
Visser et al. Page 4













percentage of those with a current ADHD diagnosis reported to be in treatment was 
compared between 2007 and 2011.
Results
All ADHD survey indicators extended from parent-reported data for children aged 4–17 
years; for brevity, the term “parent-reported” and age (4–17 years) is excluded as a qualifier 
of the relevant estimates that follow.
2011 Ever-diagnosed and Current ADHD Prevalence Estimates and Demographic Patterns
In 2011, the estimated prevalence of ever-diagnosed ADHD among children was 11.0%, 
representing 6.4 million children nationwide (Table 1). Among children with ever-diagnosed 
ADHD, 82.3% had current ADHD resulting in an estimated national prevalence of 8.8% 
among children (5.1 million nationwide).
ADHD diagnosis (ever and current) was significantly associated (p < 0.05 based on X2 
statistics) with every demographic indicator studied. Ever-diagnosed ADHD was higher 
among boys (15.1%) than girls (6.7%) and increased with age (Table 1). The highest point 
estimates were among boys (15.1%), children 11 and older (11–14 years: 14.3%, 15–17 
years: 14.0%), and children with public health care coverage (14.4%). Prevalence was 
higher for black and white children compared to those of other races; the prevalence among 
Hispanics was half that of non-Hispanics. Those living in households where English is the 
primary language were more than four times as likely to have been diagnosed as those living 
in households speaking another primary language. Prevalence was highest among children 
from households with 12 years (high school graduate) of education, compared to households 
with more or less education. Children living below 200% of the federal poverty level had a 
higher prevalence than children from higher income families. Ever-diagnosed ADHD was 
more common among children with health care coverage than those without coverage, and 
among those with public coverage than with private coverage. Ever-diagnosed ADHD was 
lowest in the West, compared to other US regions.
The demographic and state-based patterns for current ADHD were generally consistent with 
those observed for ever-diagnosed ADHD, although current ADHD estimates were 
approximately 20–25% lower than ever-diagnosed estimates (Table 1). State-based 
estimates of current ADHD ranged from 4.2% in Nevada to 14.6% in Arkansas and 14.8% 
in Kentucky (Figure 1).
Among children with current ADHD, the median age of diagnosis was 6.2 years (95% CI 
6.1–6.4; mean=7.0, 95% CI 6.9–7.2). Age of diagnosis decreased with severity; children 
whose parents reported the child’s ADHD as “mild” were diagnosed at a median age of 7.0 
years (95% CI 6.8–7.3; mean=7.8, 95% CI 7.5–8.1), compared to 6.1 (95% CI 5.8–7.3; 
mean=6.9, 95% CI 6.7–7.1) and 4.4 (95% CI 4.1–4.7; mean=5.1, 95% CI: 4.9–5.5) years for 
those with “moderate” and “severe” ADHD, respectively.
2011 Medication Treatment for Current ADHD—Estimated prevalence of medication 
treatment for ADHD among US children was 6.1% (3.5 million nationwide). Of those with a 
Visser et al. Page 5













current ADHD diagnosis, 69.0% were taking ADHD medication. ADHD medication 
treatment estimates were significantly associated with every demographic indicator studied 
(p < 0.05 by X2statistics). The highest point estimates of parent-reported ADHD medication 
treatment were observed among boys (8.4%), whites (7.1%), non-Hispanics (7.0%), children 
living in households speaking English as the primary language (7.0%), children with public 
health care coverage (8.1%), and children living in the Midwest (7.1%) and South (7.3%; 
Table 1). After increasing with age from 4–10 years to 11–14 years, current medication 
treatment prevalence decreased slightly among children 15–17 years of age. Current 
medication treatment was lowest among children in households speaking a primary language 
other than English (0.9%). State-based estimates ranged from 2.0% in Nevada to 10.0% in 
Kentucky and 10.4% in Louisiana (Figure 2).
The proportion of children taking medication for ADHD increased with ADHD severity: 
59.6% (95% CI 55.6–63.5) for “mild” ADHD, 73.3% (95% CI: 69.2–77.0) for “moderate” 
ADHD, and 82.4% (95% CI: 76.0–87.3) for “severe” ADHD. The percentage of children 
with current ADHD who received any treatment or counseling from a mental health 
professional was 51.0% (95% CI 48.4–53.7). The percentage of children receiving either 
medication for ADHD or mental health treatment was 82.5% (95% CI 80.5–84.4).
Trends in Parent-reported ADHD Indicators over Time
Ever-diagnosed and Current ADHD—Estimated prevalence of ever-diagnosed ADHD 
was 7.8%, 9.5%, and 11% in 2003, 2007, and 2011, respectively (Table 2). These estimates 
increased by 22% from 2003–2007 (average annual increase = 6%27) and 16% from 2007–
2011 (average annual increase = 4%). The total increase from 2003–2011 was 42% (PR = 
1.42, 95% CI 1.33–1.50; average annual increase = 5%). The only two demographic 
subgroups for which there was not a significant change in ever-diagnosed ADHD from 2003
—2011 were multiracial/other race children and children without health care coverage. The 
magnitudes of increase (slopes) from 2003—2007 and 2007—2011 were equivalent for 
every subgroup studied, with the exception of the subgroup where the highest level of 
education was high school (F1, 39956=4.05, p<0.05) and children of multiracial/other races 
(F1,24866=7.3, p<0.01), in which the magnitudes of increase were smaller for 2007—2011 
than 2003—2007. The greatest relative increases in ever-diagnosed ADHD from 2007—
2011 were among children aged 11–14 years, children living in a household with an adult 
with more than a high school education, whites, and children living in the Midwest. The 
pattern in the proportion of children with ever-diagnosed ADHD differed over time as a 
function of age (F4, 228198=2.57, p=0.0359); ever-diagnosed ADHD increased from 2003 to 
2011 for children 14 and under, but the growth leveled off for older children from 2007 to 
2011 (Table 2).
Current ADHD increased by 23%, from 7.2% to 8.8% from 2007–2011 (Table 2). The 
increases were reflected in significantly higher 2011 prevalence among children under 14 
years, children from households with at least 12 years of education, whites, non-Hispanics, 
children living in households where English was a primary language, those living in 
households with incomes above 100% of poverty, children with health care coverage, and 
children living in the Midwest and South; the greatest relative increases were seen among 
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girls, children 11–14 years of age, whites, and children living in the Midwest. Prevalence 
was statistically similar between 2007 and 2011 among those with public health care 
coverage, but increased significantly among children with private health care coverage. The 
increased prevalence of current ADHD among Hispanics did not reach statistical 
significance (p=0.06). The proportion of children with current ADHD among those with 
ever-diagnosed ADHD increased from 2007—2011, from 78.2% to 80.1% (X21=7.93, 
p<0.01). The distribution of ADHD severity shifted from 2007—2011 (mild: 46.7% vs. 
41.4%, moderate: 39.5% vs. 43.1%, severe: 13.8% vs. 15.5%; X22=3.09, p<0.05). The 
pattern in the proportion of children reported to have current ADHD over time varied as a 
function of child race (F2, 142350=6.40, p=0.0017). Specifically, the proportion of children 
with current ADHD decreased among children of multiracial/other races whereas it 
increased among children of white or black races (Table 2).
Current Medication Treatment for ADHD and Treatment by a Mental Health 
Professional—ADHD medication treatment increased 28% from 2007—2011 from 4.8% 
to 6.1% (Table 2), an average annual increase of 7%. The proportion of children taking 
medication within strata of parent-reported severity was statistically similar in 2007 and 
2011. Descriptively, the demographic groups with the greatest relative increases in current 
medication prevalence were females, 4–10 year olds, whites, children living above 100% of 
the Federal poverty level, and children living in the Midwest. The pattern in the proportion 
of children taking medication for ADHD varied as a function of child race (F2, 142676=5.59, 
p=0.0037; the proportion of children taking medication for ADHD decreased among 
children of multiracial/other races whereas it increased among children of white or black 
races (Table 2).
Although the prevalence of current mental health treatment or counseling among those with 
current ADHD remained similar from 2007—2011, the percentage of children who either 
received that treatment or were taking ADHD medication increased (78.8% to 82.5%; 
χ2=4.10, p<0.05), due to increases in ADHD medication treatment. Among those not 
receiving either of the two forms of treatment, 63.6% were reported as having mild ADHD 
(95% CI 57.8–69.1), 29.5% as moderate (95% CI 24.5–35.1), and 6.9% as severe (95% CI 
4.4–10.5).
ADHD Prevalence and Medicated Prevalence Stratified by Age and Sex—
Prevalence of ADHD diagnosis and current medication treatment for ADHD are presented 
by sex-stratified age across the three survey periods in Figure 3. Increasing prevalence over 
time can be seen from the growing size of the inverted pyramid, with a relatively consistent 
sex ratio for each indicator. Among boys, the 2003 prevalence of ever-diagnosed ADHD 
(outer bars) was less than 15%, regardless of age; in 2007, the estimates exceeded 15% for 
those 9–17, with the exception of 12-year-olds (13.9%); in 2011 the estimates exceeded 15% 
for those 10–17, and exceeded 20% for 11-year-olds and 14-year-olds. Among girls, the 
2003 prevalence of ever-diagnosed ADHD (outer bars) increased from ages 4–8, then 
stabilized at 5–6% for those 9–17; in 2007 the prevalence increased with estimates ranging 
from 5.8% among 10-year-olds to 11.6% among 16-year-olds; in 2011 the prevalence 
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ranged from just over 5% to just under 10% for all but 14-year-olds, for whom the estimated 
prevalence of ever-diagnosed ADHD was 11.8%.
The medication treatment question was asked of parents reporting ever-diagnosed ADHD in 
2003 and parents reporting current ADHD in 2007 and 2011. In 2003, medicated ADHD 
prevalence increased from ages 4–9, stabilized, and then decreased in the teen years for both 
sexes. Estimates of medicated ADHD increased in 2011, as compared to 2007 particularly 
among teen boys. In 2011, the highest medicated ADHD prevalence was among 11-year-old 
boys (13.3%). Among girls, medicated ADHD remained under 5% until 2011 when the 
estimates met or exceeded 5% for girls aged 9–10 and 14–15.
Discussion
The epidemiological profile for ADHD diagnosis and treatment continues to evolve. Based 
on parent-reported indicators of health care provider-diagnosed ADHD diagnosis and 
treatment, more than one in ten (11%) school-aged children had received an ADHD 
diagnosis by a health care provider by 2011, representing over 6.4 million children 
nationally. Nearly 1 in 5 high school boys and 1 in 11 high school girls had been diagnosed 
with ADHD. Of those with a history of ADHD, 83% had current ADHD in 2011 (8.8% 
nationwide) and 69% of these children (6.1% nationwide) were taking medication for 
ADHD. These estimates are all significantly higher than comparable 2007 estimates.27 
Specifically, after a 22% increase in parent-reported history of ADHD diagnosis from 2003
—2007, the prevalence increased another 16% from 2007—2011; a total increase of 42% 
from 2003—2011. Medicated ADHD among children living in the US increased by 27% 
from 2007—2011. Among children with a history of ADHD, proportionately more had 
current ADHD in 2011, as compared to 2007. Taken together, an estimated two million 
more American children were diagnosed with ADHD and a million more were taking 
ADHD medication in 2011 compared to 2003.
This study reveals a number of important and consistent demographic patterns for ADHD 
diagnosed by health care providers. Parent-report of ADHD diagnosis increased for most 
demographic subgroups; however, after increasing significantly from 2003—2007, the 
prevalence of a history of ADHD diagnosis was statistically similar between 2007 and 2011 
among older teens and decreased among children who were multiracial/of other races.
Direct comparisons of the 2003 to the other medication indicators were not appropriate. 
From 2007—2011, medicated ADHD prevalence increased overall but remained statistically 
similar among children who were multiracial/of other races. Medicated ADHD estimates 
within each ADHD severity strata were statistically similar during this time period. The 
estimated treated prevalence of ADHD (mental health treatment plus medication) increased 
from 2007—2011, due to increases in medicated ADHD; however as many as 17.5% of 
children with current ADHD were not receiving one of the forms of treatment for ADHD in 
2011, more than one-third of which were moderate and severe cases.
The findings in this report are subject to several limitations. First, as noted earlier, the 
ADHD indicators used in this report did not assess ADHD symptoms directly but rather 
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relied on parent-report of diagnosis by a health care provider, which may introduce recall 
bias. The parent-reported indicators have not been clinically validated, however a recent 
analysis indicated that parent-reported survey data produced similar estimates as those from 
insurance claims data, providing evidence of convergent validity for parent-reported ADHD 
diagnosis by a health care provider.32 Second, the cell-phone sample inclusion could have 
affected the 2011 estimates; analyses of restricted-use data suggest that children living in 
cell-phone-only households in 2011 were more likely to have current ADHD than children 
living in landline households (10.0% vs. 8.4%), therefore non-coverage of cell-phone only 
households in 2007 may have underestimated prevalence. Third, survey responses were 
limited to those who agreed to participate and response rates in 2011 were lower than those 
in 2003 and 2007; however, nonresponse bias is attenuated by the inclusion of demographic 
factors in the sample weight calculations; however non-response bias cannot be ruled out. 
Fourth, although medication treatment and mental health treatment indicators were included 
in this study, other forms of treatment for ADHD were not collected and estimates of ADHD 
treatment may therefore underestimate treated prevalence. Finally, the cross-sectional data 
in this report cannot be used to determine the cause of increased prevalence or the 
appropriateness of diagnosis or medication treatment. However, these data do allow for 
ecological analyses of changes in policies and demographic characteristics, as conducted by 
Fulton and colleagues.33
The increasing prevalence estimates of parent-reported ADHD diagnosis are generally 
consistent with previous rates of increase. These increases could indicate that the actual 
prevalence of underlying ADHD has increased consistently over time, however the proxy 
data used in this report prohibits drawing firm conclusions about changes in the underlying 
prevalence of ADHD. The increases could also reflect better detection of underlying ADHD, 
due to increased health education and awareness efforts. A number of contextual factors are 
known to influence the frequency with which childhood ADHD is diagnosed, including 
increased awareness efforts, educational policies, physician characteristics, cultural factors, 
and changes in public perception.33–36 Other factors, such as increased confidence to treat 
ADHD among clinicians and increased exposure to etiologic factors (e.g., environmental 
contaminants) may also play a role. The magnitude of increases documented with these 
cross-sectional data warrant future efforts to more fully understand the factors impacting 
ADHD diagnosis.
The increases in parent-reported medication for ADHD is consistent with previous 
research28 and should be considered within a broad context. Medication treatment is the 
single-most effective ADHD treatment, resulting in immediate and meaningful 
improvements in ADHD symptoms that surpass the efficacy of behavioral therapy 
alone.11,12 The effectiveness of ADHD medication on ADHD symptoms has likely 
contributed to the ADHD medication initiation and continuance. However, we do not fully 
understand the long-term impact of taking ADHD medication over time. There is some 
evidence that long-term ADHD medication normalizes right dorsolateral prefrontal cortex 
activation.37 There is also conflicting evidence about the risk and protective effects of 
ADHD medication use and later substance use among adolescents and young adults.38,39 
Functional outcomes are also consistently and heavily influenced by symptom trajectory, 
socio-demographic factors, and treatment history.40 Given the increasing medication 
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treatment patterns and the developing literature about the risks of both intervening and 
failing to intervene, continued research on the long-term benefits of ADHD treatment, both 
pharmacological and behavioral, is needed.
Considering the overall national context, the increases in parent-reported ADHD diagnosis 
and associated medication treatment occurred during a period in which the FDA issued three 
Public Health Alerts and a series of communications regarding cardiac and psychiatric risks 
of ADHD medications.41,42 Others have documented upward trends in ADHD medication 
treatment despite these safety alerts, which contrast with the downward trends seen in 
pediatric antidepressant use following alerts regarding suicidality.41,43,44 Prevalence of 
ADHD medication use also increased despite an overall downward trend in pediatric 
medication prescriptions.45 Notably, there has been an increase in antipsychotic medication 
use among children, including concomitant use of multiple psychotropic medications, with 
the most common combination being ADHD medication and an antidepressant.46,47 Finally, 
the 2011 medication treatment estimates may have been somewhat constrained by the 
ADHD medication shortages experienced throughout the US from 2009—2011.48,49
The findings of this report have several important clinical and public health implications. 
Parent-reported prevalence estimates provide insight into the demand that this population 
has on the systems supporting them and these data suggest that the impact of ADHD may be 
increasing. ADHD is commonly diagnosed before age 5 in children with severe ADHD; 
children diagnosed with ADHD in early childhood may benefit from targeted interventions. 
Attention to the transitional needs of the large population of high school students taking 
medication for ADHD (6.4%) may be warranted, particularly given increasing concerns 
about abuse, misuse, and diversion of medication to others.50–52 Based on this report’s 
estimates, the cross-sector costs associated with ADHD likely exceed the previously 
estimated upper bound of $52 billion.53 Future cross-Public Health system efforts should 
continue to describe and monitor ADHD diagnostic and treatment patterns, assess the 
alignment of these patterns to best practices, and seek to understand the factors influencing 
the evolving prevalence of ADHD diagnosis and treatment.
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